1090 Horsham Road
About Teva Pharmaceuticals
Teva Pharmaceutical Industries Ltd. develops, produces and markets ethical drugs, generic drugs, and fine chemicals for the pharmaceutical industry and disposable products for hospitals and home care services.
1596 articles with Teva Pharmaceuticals
The U.S. Department of Justice charged the Israel-based company with three counts of fixing prices to reap more than $350 million from customers through the scheme.
The collaboration is one of the broadest partnerships within the U.S. biosimilar industry to date to accelerate improved patient access for high quality biosimilar medicines in the U.S. biosimilar industry
Revenues of $3.9 billion GAAP diluted EPS of $0.13 Non-GAAP diluted EPS of $0.55 Free cash flow of $582 million Full year 2020 business outlook reaffirmed: Net revenues of $16.6 - $17 billion EBITDA of $4.5 - $4.9 billion EPS of $2.30 - $2.55 Free cash flow of $1.8 - $2.2 billion
Japan Business Venture shifts focus to specialty assets and a portfolio of select generics that meet patients' medical needs
Teva to Host Conference Call to Discuss Second Quarter 2020 Financial Results at 8 a.m. ET on August 5, 2020
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter financial results on Wednesday August 5, 2020 at 7:00 a.m. ET.
Teva Presents New Analyses Examining Changes in Migraine Disability Outcome Measurements with AJOVY® (fremanezumab-vfrm) Injection
Teva Presents New Analyses Examining Changes in Migraine Disability Outcome Measurements with AJOVY ® (fremanezumab-vfrm) Injection Open-label extension of the FOCUS Phase IIIb study examined changes in quality of life, health status, depressive symptoms and work productivity over 12 weeks Pooled Phase 3 results examined changes in disability using American Headache Society guidelines TEL AVIV & PARSIPPANY, N.J.--( BUSINESS WIRE )-- Tev
Teva to Present New Data on AJOVY® (fremanezumab-vfrm) Injection Open-Label Extension Study at American Headache Society Annual Meeting
Teva to Present New Data on AJOVY ® (fremanezumab-vfrm) Injection Open-Label Extension Study at American Headache Society Annual Meeting
Two weeks after announcing concerns about high-levels of carcinogens in popular diabetes drugs, the U.S. Food and Drug Administration announced the first voluntary recalls of this class of drugs manufactured by five companies.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2019 Environmental, Social and Governance (ESG) Progress Report , demonstrating the company’s social impact and responsibility performance. The report includes 2020 goals for specific topics and clear alignment with the United Nations Sustainable Development Goals. For the first time, an external reviewer validated select report content. Th
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) (“Teva”), announced today that, in the interest of the health and safety of its shareholders, directors, officers and employees in light of the current COVID-19 pandemic, the format of its 2020 Annual Meeting of Shareholders has been changed to a virtual meeting. Teva’s 2020 Annual Meeting will be held on Tuesday, June 9, 2020 at 4:30 p.m., Israel time (9:30 a.
Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine
Teva Pharmaceutical Industries Ltd. presented a wide range of important new data on AJOVY® and the societal and economic impact of migraine in Europe at the 6th Congress of the European Academy of Neurology.
Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate injection) at European Academy of Neurology Congress
Teva Pharmaceutical Industries Ltd. announced that new data on AJOVY® and the burden of migraine in Europe will be presented at the 6th Congress of the European Academy of Neurology, being held virtually from 23-26 May 2020.
China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults
Teva Pharmaceutical Industries Ltd., announced that the China National Medical Products Administration has approved AUSTEDO® for the treatment of chorea associated with Huntington's disease and Tardive Dyskinesia in adults, after a priority review.
Revenues of $4.4 billion GAAP diluted EPS of $0.06 Non-GAAP diluted EPS of $0.76 Free cash flow of $551 million Full year 2020 business outlook reaffirmed: Net revenues of $16.6 - $17 billion EBITDA of $4.5 - $4.9 billion EPS of $2.30 - $2.55 Free cash flow of $1.8 - $2.2 billion
Teva and Celltrion Healthcare Announce the Launch of TRUXIMA® (rituximab-abbs) Injection for Rheumatoid Arthritis, the Only Biosimilar to Rituxan® (rituximab) Available in the United States for This Indication
Teva and Celltrion Healthcare Announce the Launch of TRUXIMA ® (rituximab-abbs) Injection for Rheumatoid Arthritis, the Only Biosimilar to Rituxan ® (rituximab) Available in the United States for This Indication TRUXIMA is also now available for the treatment of Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)
New Data For Teva AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets Included in Neurology
New Data For Teva AJOVY ® (fremanezumab-vfrm) Injection and AUSTEDO ® (deutetrabenazine) Tablets Included in Neurology 23 abstracts appeared in the 2020 American Academy of Neurology (AAN) Science Highlights Supplement
Teva Canada Announces the Launch of AJOVY™ For the Preventive Treatment of Migraine in Adults Who Have at Least Four Migraine Days Per Month
AJOVY™ is the first and only anti-CGRP treatment with both quarterly and monthly dosing for the preventive treatment of migraine in adults
Shares of Eagle Pharmaceuticals and Teva Pharmaceuticals are climbing following a favorable ruling in U.S. District Court that protects the patent for cancer drug Bendeka from generic competition through 2031.
Court Issues Favorable Patent Litigation Decision for Eagle Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd. for BENDEKA (bendamustine hydrochloride injection)
Eagle Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd. announced that on April 27, 2020, the U.S. District Court for the District of Delaware has issued a patent decision in favor of Eagle and Teva for BENDEKA®, a liquid, low-volume and short-time 10-minute infusion formulation of bendamustine hydrochloride..
Teva Announces U.S. Launch of Autoinjector for AJOVY ® (fremanezumab-vfrm) Injection